[18]Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 t...
[18]Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 t...
[5]Tolaney SM,Tarantino P,Graham N,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer:final 10-year analysis of the open-label,single-arm,phase 2 APT trial.Lancet Oncol.2023 Mar;24(3):273-285. [6]Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxe...
8. Laura Morsberger, Aparna Pallavajjala , Patty Long, et al.HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry. Cancer Cell Int. 2022 Nov 15;22(1):350.
[14] Morsberger L, Pallavajjala A, Long P, et al. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry. Cancer Cell Int. 2022 Nov 15;22(1):350. [15] Sheng WQ,...
[2].Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 1;26(5):1105-1113.[3].Rugo HS, Rumble RB, Macrae E, ...
1、GS4-10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. 2021 SABCS 2、Yi Z, Rong G, Guan Y, et al. Molecular landscape and efficacy of HER...
并建立预后列线图模型,以指导该类患者的后续治疗,该研究同时被2020 SABCS大会收录(摘要号:PS10-39,题目:Risk factors for all-cause death and breast cancer-specific death in patients with HER2-positive and lymph node negative breast cancer : A retrospective analysis based on SEER database(2010 to ...
尽管HER2低表达乳腺癌能够从新型抗HER2治疗药物中获益,但HER2低表达的临床特征和预后意义尚待进一步明确,并且目前尚未评价HER2阳性和HER2低表达乳腺癌的转移模式是否存在临床相似性。一项长期随访的大型队列研究显示,乳腺癌总体脑转移发生率为6.9%,其中HER2阴性患者、HER2低表达患者、HER2阳性患者的脑转移发生率分别为5.1%...
近日在npj Breast Cancer期刊上发表了题为“Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer”的研究,比较了TNBC和HR阴性HER2阳性的肿瘤患者的肿瘤免疫微环境,以探索其潜在的相似或不同之处。肿瘤免疫微环境: HER2 阳性乳腺癌患者...